NZ737471A - Hydrophilic linkers for conjugation - Google Patents
Hydrophilic linkers for conjugationInfo
- Publication number
- NZ737471A NZ737471A NZ737471A NZ73747115A NZ737471A NZ 737471 A NZ737471 A NZ 737471A NZ 737471 A NZ737471 A NZ 737471A NZ 73747115 A NZ73747115 A NZ 73747115A NZ 737471 A NZ737471 A NZ 737471A
- Authority
- NZ
- New Zealand
- Prior art keywords
- conjugation
- hydrophilic linkers
- hydrophilic
- linkers
- conjugates
- Prior art date
Links
- 230000021615 conjugation Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000005541 phosphonamide group Chemical group 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
Abstract
Cell binding agent-drug conjugates comprising hydrophilic phosphonamide or sulfonamide linkers, methods synthesis thereof, and use of the conjugates in therapy.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2015/054521 WO2015151078A2 (en) | 2015-06-15 | 2015-06-15 | Hydrophilic linkers for conjugation |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ737471A true NZ737471A (en) | 2022-02-25 |
Family
ID=54241395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ737471A NZ737471A (en) | 2015-06-15 | 2015-06-15 | Hydrophilic linkers for conjugation |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3307749A4 (en) |
CN (2) | CN112125929A (en) |
AU (3) | AU2015242210A1 (en) |
CA (1) | CA2989269C (en) |
NZ (1) | NZ737471A (en) |
WO (1) | WO2015151078A2 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2872157T (en) | 2012-07-12 | 2020-04-30 | Hangzhou Dac Biotech Co Ltd | Conjugates of cell binding molecules with cytotoxic agents |
US11873281B2 (en) | 2012-07-12 | 2024-01-16 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of cell binding molecules with cytotoxic agents |
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
CA3006000A1 (en) * | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
CA3020864A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
AU2017292934B2 (en) | 2016-07-07 | 2024-04-04 | Bolt Biotherapeutics, Inc. | Antibody adjuvant conjugates |
JP7300394B2 (en) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death |
CA3058712C (en) * | 2017-04-06 | 2023-04-18 | Hangzhou Dac Biotech Co., Ltd | Conjugation of a cytotoxic drug with bis-linkage |
DK3641824T3 (en) * | 2017-06-21 | 2022-11-21 | Glykos Finland Oy | HYDROPHILIC LINKERS AND CONJUGATES THEREOF |
DK3658192T3 (en) | 2017-12-01 | 2021-06-21 | Abbvie Inc | GLUCOCORTICOID RECEPTORAGONIST AND ITS IMMUNOCONJUGATES |
WO2019109415A1 (en) * | 2017-12-04 | 2019-06-13 | 清华大学 | Compound for targeted degradation of hmgcr and application thereof |
AU2017445144A1 (en) * | 2017-12-31 | 2020-06-18 | Hangzhou Dac Biotech Co. Ltd | A conjugate of a tubulysin analog with branched linkers |
CN110152014B (en) * | 2018-02-13 | 2022-09-27 | 烟台市和元艾迪斯生物医药科技有限公司 | anti-TRAILR 2 antibody-toxin-conjugate and its pharmaceutical use in anti-tumor therapy |
WO2019157772A1 (en) * | 2018-02-13 | 2019-08-22 | 和元生物技术(上海)股份有限公司 | Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy |
CN108727376B (en) * | 2018-05-21 | 2020-09-11 | 中国计量大学 | 9-azabicyclo [3.3.1] nonane coupled iodine-enriched compound and preparation method and application thereof |
CN108676002B (en) * | 2018-06-04 | 2020-09-15 | 中国计量大学 | 9-nitrogen (6' -amino) hexyl heterobicyclo [3.3.1] nonane coupled rhodamine B compound and application thereof |
CN108864251B (en) * | 2018-06-30 | 2022-06-14 | 大连理工大学 | Aminopeptidase N activated prodrug compound and preparation method and application thereof |
MX2021003295A (en) * | 2018-09-27 | 2021-07-16 | Pf Medicament | Sulfomaleimide-based linkers and corresponding conjugates. |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
US11826430B2 (en) | 2019-05-14 | 2023-11-28 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CN112386707B (en) * | 2019-08-19 | 2023-08-11 | 辽宁医学诊疗科技研发中心有限公司 | Tumor targeting polypeptide drug conjugate and preparation method thereof |
CN110938035B (en) * | 2019-10-28 | 2022-07-01 | 广西师范大学 | 9-benzenesulfonic acid-10-imidine hydrazone and synthetic method and application thereof |
TW202131930A (en) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | Anti-cancer nuclear hormone receptor-targeting compounds |
CN113135990A (en) * | 2020-01-20 | 2021-07-20 | 宁波鲲鹏生物科技有限公司 | Liraglutide derivatives and preparation method thereof |
EP3862023A1 (en) * | 2020-02-05 | 2021-08-11 | Hangzhou DAC Biotech Co, Ltd | Conjugates of cell-binding molecules with cytotoxic agents |
CN113816990B (en) * | 2021-03-22 | 2023-08-22 | 联宁(苏州)生物制药有限公司 | Modified amino acids and their use in ADCs |
BR112023019420A2 (en) | 2021-03-23 | 2023-10-24 | Nuvation Bio Inc | ANTI-CANCER NUCLEAR HORMONE RECEPTOR TARGETING COMPOUNDS |
CN114200126A (en) * | 2021-12-09 | 2022-03-18 | 牟奕 | Solid phase matrix for detecting N-type penicillin and cephalosporin antibiotic antibodies and preparation method thereof |
WO2023129576A2 (en) * | 2022-01-03 | 2023-07-06 | Lilac Therapeutics, Inc. | Acyclic thiol prodrugs |
CN115286669A (en) * | 2022-07-15 | 2022-11-04 | 北京大学 | Preparation method and application of antibody-macromolecule-drug conjugate |
CN116773826B (en) * | 2023-08-21 | 2023-11-17 | 迪亚莱博(张家港)生物科技有限公司 | Latex turbidimetric biochemical kit for detecting anti-protease 3 antibody |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4003862A (en) * | 1975-10-23 | 1977-01-18 | Michigan Chemical Corporation | N-substituted tetrahalophthalimides as flame retardants |
EP2102144A4 (en) * | 2006-09-13 | 2011-03-23 | Univ Rutgers | Active agents and their oligomers and polymers |
WO2008070291A2 (en) * | 2006-10-24 | 2008-06-12 | Kereos, Inc. | Improved linkers for anchoring targeting ligands |
RU2523909C2 (en) * | 2007-06-25 | 2014-07-27 | Эндосайт, Инк. | Conjugates, containing hydrophilic spacers of linkers |
ES2701076T3 (en) * | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells |
CN104650113A (en) * | 2012-12-21 | 2015-05-27 | 百奥泰生物科技(广州)有限公司 | Maytansine derivative as well as preparation method and application thereof |
EP3041846B1 (en) * | 2013-09-02 | 2018-11-07 | Hangzhou Dac Biotech Co., Ltd | Novel cytotoxic agents for conjugation of drugs to cell binding molecule |
US10550190B2 (en) * | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
JP6733993B2 (en) | 2014-10-03 | 2020-08-05 | シンアフィックス ビー.ブイ. | Sulfamide linker, conjugate of sulfamide linker, and method of preparation |
-
2015
- 2015-06-15 NZ NZ737471A patent/NZ737471A/en unknown
- 2015-06-15 AU AU2015242210A patent/AU2015242210A1/en not_active Abandoned
- 2015-06-15 CN CN202011053870.7A patent/CN112125929A/en active Pending
- 2015-06-15 CN CN201580080839.3A patent/CN108026123B/en active Active
- 2015-06-15 EP EP15773860.0A patent/EP3307749A4/en active Pending
- 2015-06-15 WO PCT/IB2015/054521 patent/WO2015151078A2/en active Search and Examination
- 2015-06-15 CA CA2989269A patent/CA2989269C/en active Active
-
2021
- 2021-03-22 AU AU2021201765A patent/AU2021201765B2/en active Active
-
2023
- 2023-02-17 AU AU2023200925A patent/AU2023200925A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2023200925A1 (en) | 2023-03-23 |
CN108026123A (en) | 2018-05-11 |
WO2015151078A4 (en) | 2016-07-14 |
WO2015151078A2 (en) | 2015-10-08 |
CA2989269A1 (en) | 2015-10-08 |
AU2015242210A1 (en) | 2017-12-07 |
AU2021201765A1 (en) | 2021-04-15 |
AU2021201765B2 (en) | 2022-12-08 |
CN112125929A (en) | 2020-12-25 |
EP3307749A2 (en) | 2018-04-18 |
EP3307749A4 (en) | 2019-06-19 |
CN108026123B (en) | 2021-02-05 |
WO2015151078A3 (en) | 2016-03-10 |
CA2989269C (en) | 2020-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ737471A (en) | Hydrophilic linkers for conjugation | |
EP3538080A4 (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
MX2021010550A (en) | Hydrophilic antibody-drug conjugates. | |
HK1259487A1 (en) | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | |
WO2015151080A3 (en) | Specific conjugation of cell-binding molecules | |
SA518391159B1 (en) | Affinity-Oligonucleotide Conjugates and Uses Thereof | |
MX2019008413A (en) | Immunoengineered pluripotent cells. | |
IL279133A (en) | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto | |
PH12016501618A1 (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
NZ746680A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
TW201613962A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
MX2021008334A (en) | Stability-modulating linkers for use with antibody drug conjugates. | |
EP4302782A3 (en) | Napi2b-targeted antibody-drug conjugates and methods of use thereof | |
PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
MX2014011134A (en) | Carbamate compounds and of making and using same. | |
MY187540A (en) | Compounds active towards bromodomains | |
WO2014062697A3 (en) | Drug delivery conjugates containing unnatural amino acids and methods for using | |
IN2015DN02577A (en) | ||
SG10201809628SA (en) | Anti-ptk7 antibody-drug conjugates | |
EP3256495A4 (en) | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins | |
MY181994A (en) | Immuno-modulatory progenitor (imp) cell | |
EP3242688A4 (en) | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers | |
EP3271329A4 (en) | Novel hydrophilic linkers and ligand-drug conjugates thereof | |
IN2015MN00001A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUN 2024 BY CPA GLOBAL Effective date: 20230504 |